KYNTRA BIO, INC. (KYNB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$5.14

From 52W high−52.77%

Volume21485.00

Market cap$21.38M

P/E (TTM)0.1x

P/S (TTM)4.6x

Div yield—

Key dataOct 19, 2026

Open

$5.14

From 52W high

−52.77%

Volume

21485.00

Market cap

$21.38M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.5x

P/E (TTM)

0.1x

RSI (14)

26.0

MomentumView details →

1D Return

+8.87%

YTD Return

−41.51%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

0.1x

EV/EBITDA

0.5x

EV/Sales

−10.4x

P/S (TTM)

4.6x

P/B (TTM)

−0.7x

ProfitabilityView details →

Gross Margin

18.15%

Net Margin

3967.77%

EBITDA Margin

−2036.00%

ROE (TTM)

−607.72%

ROA (TTM)

181.24%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+106.34%

EPS YoY

+3782.91%

FCF YoY

−60.65%

Revenue CAGR 3Y

−64.23%

EPS CAGR 3Y

+9552.08%

EBITDA YoY

+27.17%

MomentumView details →

1D Return

+8.87%

YTD Return

−41.51%

1Y Return

−53.90%

RSI (14)

26.0

vs 50D SMA

−27.54%

vs 200D SMA

−29.67%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

2.69x

Quick Ratio

2.59x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$2.96

EPS Surprise

193.08%

Beats (12Q)

4/12

Next Q EPS Est

−$4.28

Avg Surprise (4Q)

47.21%

Rev Surprise

−171.78%

Financials snapshotView financials →

Revenue (TTM)

4.62M

Net Income (TTM)

183.19M

Op. CF (TTM)

−38.05M

Next earningsNov 9, 2026 →

Latest newsMore news →

KYNTRA BIO, INC. reported receiving a NASDAQ, INC. notice concerning noncompliance with Rule 5450(b) and requested a hearing.13d ago

Kyntra Bio, Inc. appointed Andrew E. Singer as a Class III director effective October 1, 2026.19d ago

Similar companies

Sanai Health Industry Group Company Limited01889.HK PetMed Express, Inc.PETS Neuphoria Therapeutics Inc.NEUP Pa Shun International Holdings Limited00574.HK 111, Inc.YI AIxCrypto Holdings, Inc.AIXC Find similar companies →

Latest newsMore news →

KYNTRA BIO, INC. reported receiving a NASDAQ, INC. notice concerning noncompliance with Rule 5450(b) and requested a hearing.13d ago Kyntra Bio, Inc. appointed Andrew E. Singer as a Class III director effective October 1, 2026.19d ago